Generic replacement of clozapine: A simple decision model from a Canadian perspective

Current Medical Research and Opinion

Volumn 20, Issue 4, 2004, Pages 453-459

  Layton, Stephen ^a   Barbeau, Martin ^b  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

Clozapine; Cost; Generic drugs; Relapse; Schizophrenia; Therapeutic equivalency

Indexed keywords

CLOZAPINE; GENERIC DRUG;

COHORT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; HUMAN; PREDICTION; RELAPSE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CANADA; CLOZAPINE; COST SAVINGS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; DRUGS, GENERIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, ECONOMIC; RECURRENCE; SCHIZOPHRENIA;

EID: 1942470500     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003250     Document Type: Review

References (42)

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000;250:274-85
2. Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997;42:139-51
3. Carpenter Jr. WT, Buchanan RW. Schizophrenia. New Engl J Med 1994;330:681-90
4. Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 1993;16:413-23
5. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997;171:509-18
6. De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998;24:519-27
7. Evers SM, Ament AJ. Costs of schizophrenia in The Netherlands. Schizophr Bull 1995;21:141-53
8. Genduso LA, Haley JC. Cost of illness studies for schizophrenia: components, benefits, results, and implications. Am J Manag Care 1997;3:873-7
9. Kane JM. Schizophrenia. New Engl J Med 1996;334:34-41
10. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(Suppl. 4):S397-S403
11. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Safety 2000;22:195-214
12. Therapeutic choices, 4th ed. Ottawa: Canadian Pharmacists Association, 2003
13. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997;23:663-74
14. Novartis Pharmaceuticals Canada Inc. Product monograph: Clozaril®. 2003
15. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;(Suppl 17):41-5
16. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New Engl J Med 1997;337:809-15
17. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155:499-504
18. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156:294-8
19. Sharif ZA, Raza A, Ratakonda SS. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. J Clin Psychiatry 2000;61:498-504
20. Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46:73-7
21. Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998;59:585-8
22. Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-4
23. Flynn SW, MacEwan GW, Altman S, et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998;31:25-9
24. Lindenmayer JP, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998;59:521-7
25. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl J Med 1993;329:162-7
26. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-8
27. Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. A UK clinic-based study. Br J Psychiatry 1997;171:125-30
28. Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol 2001;8:199-206
29. Center for Drug Evaluation and Research. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. 2000. http://www.fda.gov/cder/guidance/3615fnl.pdf. [Accessed 9 Dec 2003]
30. Center for Drug Evaluation and Research. Guidance: clozapine tablets: in vivo bioequivalence and in vitro dissolution testing. 1996. http://www.fda.gov/cder/guidance/clozbio.pdf [Accessed 9 Dec 2003]
31. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res 1994;11:1221 [Erratum 11:1847]
32. Lam YW, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001;62(Suppl 5): 18-22
33. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578-92
34. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001;62 (Suppl 5):14-7
35. Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001;23:1720-31
36. Stoner SC, Lea JW, Dubisar B, et al. A program to convert patients from trade-name to generic clozapine. Pharmacotherapy 2003;23:806-10
37. Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001;35:281-4
38. Tse G, Thompson D, Procyshyn RM. Generic clozapine: a cost-saving alternative to brand name clozapine? Pharmacoeconomics 2003;21:1-11
39. British Columbia Ministry of Health Services. Pharmacare Formulary. 2003
40. Ontario Ministry of Health. Schedule of Benefits: Physician Services under the Health Insurance Act. 2000
41. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
42. Makela EH, Cutlip WD, Stevenson JM, et al. Branded versus generic clozapine for treatment of schizophrenia. Ann Pharmacother 2003;37:350-3